Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database
Jiachen Tu, Zhe Wang, Jingjing Zhang, Haojie Xu, Yanming Li, Li Zhang, Jian Gong, Libo Zhao · 2026
Read Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database by Jiachen Tu, Zhe Wang, Jingjing Zhang, Haojie Xu, Yanming Li, Li Zhang, Jian Gong, Libo Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585522.txt.
Description
Jiachen Tu and seven co-authors compare the safety profiles of four BTK inhibitor drugs in this 2026 paper. These drugs treat B cell cancers, and newer generations were designed to hit fewer off targets. The team mined the United States adverse event database, FAERS, for reports on all four drugs. They ran four signal detection methods and added a scoring step to rank clinical importance.
The data held 77,014 adverse event reports. All four drugs showed signals for blood, heart, and infection problems. The details split by drug. The oldest, ibrutinib, stood out for heart rhythm signals and for links with fatal outcomes. Acalabrutinib showed a distinct headache signal. Zanubrutinib signaled low blood counts and skin bleeding. Pirtobrutinib, the newest, signaled raised white cell counts most strongly. The authors frame the study as surveillance evidence, not proof of cause.
Catalog record
| CREATOR | Jiachen Tu, Zhe Wang, Jingjing Zhang, Haojie Xu, Yanming Li, Li Zhang, Jian Gong, Libo Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 101 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |